TLRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tilray Brands Inc (TLRY) is not a strong buy for a beginner, long-term investor at this time. While the company shows potential in its diversified operations and recent acquisitions, its financial performance and technical indicators do not currently support a compelling entry point. The lack of significant positive trading signals and the mixed analyst sentiment further suggest holding off on investment until clearer growth trends or catalysts emerge.
The technical indicators for TLRY are mixed. The MACD is slightly positive, but the RSI is neutral at 40.666, showing no clear momentum. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. The stock is trading below the pivot level of 6.651, with key support at 6.261 and resistance at 7.041.
Tilray's diversified operations in cannabis, beverages, and wellness industries, along with its global presence, provide potential for long-term growth. The company is the largest cannabis company by revenue in Canada and has shown growth in international sales and Canadian adult-use performance.
Tilray's financials show declining net income (-47.35% YoY) and EPS (-58.59% YoY), despite a slight revenue increase (3.11% YoY). Analyst sentiment is neutral to cautious, with lowered price targets and concerns about U.S. legislative outcomes and regulatory headwinds. The stock also faces potential challenges in the beer market and a possible ban on intoxicating hemp products in late 2026.
In Q2 2026, Tilray's revenue increased by 3.11% YoY to $217.5M, but net income dropped significantly by 47.35% YoY to -$44.93M. EPS also declined by 58.59% YoY to -0.41. However, gross margin improved by 34.60% YoY to 24.43%, indicating some operational efficiency gains.
Analysts maintain a neutral stance on TLRY, with recent price target reductions from multiple firms. Alliance Global lowered its target to $9 from $10, citing the importance of synergies from recent acquisitions. Roth Capital also reduced its target to $10 from $20, highlighting the dependency on U.S. legislative outcomes. Canaccord initiated coverage with a Hold rating, citing structural inefficiencies in the cannabis market and challenges in the beer industry.
